Latest news with #QimingVenturePartners
Globe and Mail
20-05-2025
- Business
- Globe and Mail
Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners
HONG KONG , May 20, 2025 /CNW/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a new investor, alongside continued support from Qiming Venture Partners. This latest investment, following Pulnovo Medical's recent CE-MDR certification in Europe , marks a major step forward in expanding treatment options for patients with pulmonary hypertension globally. It is expected to accelerate the company's global expansion by supporting international clinical trials, regulatory approvals, indication expansion, and commercialization. Founded in 2013, Pulnovo Medical addresses a critical unmet need in cardiovascular care by developing a first-in-class medical device based on pulmonary artery denervation (PADN) core technology. It was awarded US FDA Breakthrough Device designation in 2021 and FDA Humanitarian Use Device designation in 2023. Its catheter and generator received China NMPA Approval as a breakthrough device in late 2023, followed by FDA clearance of the 9F sheath in 2024. In March 2025 , the company obtained CE-MDR certification, marking a key milestone toward global commercialization. Zoe Zhu , Director in the EQT Private Capital Asia advisory team said: "Globally there is a significant unmet clinical need for patients with pulmonary hypertension and heart failure, Pulnovo's PADN solution offers new hopes for these patients with strong clinical evidence supporting improved outcomes and growing endorsement from the global medical community. EQT is excited to support Pulnovo Medical by leveraging our deep expertise in healthcare and life sciences, along with our global network, to help advance their mission of delivering novel cardiovascular solutions to patients in need worldwide." Cynthia Chen , Chairwoman and Executive Chair of Pulnovo Medical, stated: "We sincerely thank EQT and Qiming Venture Partners for their continued trust and partnership. Since day one, Pulnovo Medical has remained focused on addressing real, unmet clinical needs—developing original, scalable, and evidence-based solutions rooted in frontline care. While the path to transforming clinically driven innovation into global standards is challenging, we remain committed to delivering meaningful, science-based medical value to patients around the world."
Yahoo
20-05-2025
- Business
- Yahoo
Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners
HONG KONG, May 20, 2025 /CNW/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a new investor, alongside continued support from Qiming Venture Partners. This latest investment, following Pulnovo Medical's recent CE-MDR certification in Europe, marks a major step forward in expanding treatment options for patients with pulmonary hypertension globally. It is expected to accelerate the company's global expansion by supporting international clinical trials, regulatory approvals, indication expansion, and commercialization. Founded in 2013, Pulnovo Medical addresses a critical unmet need in cardiovascular care by developing a first-in-class medical device based on pulmonary artery denervation (PADN) core technology. It was awarded US FDA Breakthrough Device designation in 2021 and FDA Humanitarian Use Device designation in 2023. Its catheter and generator received China NMPA Approval as a breakthrough device in late 2023, followed by FDA clearance of the 9F sheath in 2024. In March 2025, the company obtained CE-MDR certification, marking a key milestone toward global commercialization. Zoe Zhu, Director in the EQT Private Capital Asia advisory team said: "Globally there is a significant unmet clinical need for patients with pulmonary hypertension and heart failure, Pulnovo's PADN solution offers new hopes for these patients with strong clinical evidence supporting improved outcomes and growing endorsement from the global medical community. EQT is excited to support Pulnovo Medical by leveraging our deep expertise in healthcare and life sciences, along with our global network, to help advance their mission of delivering novel cardiovascular solutions to patients in need worldwide." Cynthia Chen, Chairwoman and Executive Chair of Pulnovo Medical, stated: "We sincerely thank EQT and Qiming Venture Partners for their continued trust and partnership. Since day one, Pulnovo Medical has remained focused on addressing real, unmet clinical needs—developing original, scalable, and evidence-based solutions rooted in frontline care. While the path to transforming clinically driven innovation into global standards is challenging, we remain committed to delivering meaningful, science-based medical value to patients around the world." View original content: SOURCE Pulnovo Medical View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
20-05-2025
- Business
- Cision Canada
Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners
HONG KONG, May 20, 2025 /CNW/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a new investor, alongside continued support from Qiming Venture Partners. This latest investment, following Pulnovo Medical's recent CE-MDR certification in Europe, marks a major step forward in expanding treatment options for patients with pulmonary hypertension globally. It is expected to accelerate the company's global expansion by supporting international clinical trials, regulatory approvals, indication expansion, and commercialization. Founded in 2013, Pulnovo Medical addresses a critical unmet need in cardiovascular care by developing a first-in-class medical device based on pulmonary artery denervation (PADN) core technology. It was awarded US FDA Breakthrough Device designation in 2021 and FDA Humanitarian Use Device designation in 2023. Its catheter and generator received China NMPA Approval as a breakthrough device in late 2023, followed by FDA clearance of the 9F sheath in 2024. In March 2025, the company obtained CE-MDR certification, marking a key milestone toward global commercialization. Zoe Zhu, Director in the EQT Private Capital Asia advisory team said: "Globally there is a significant unmet clinical need for patients with pulmonary hypertension and heart failure, Pulnovo's PADN solution offers new hopes for these patients with strong clinical evidence supporting improved outcomes and growing endorsement from the global medical community. EQT is excited to support Pulnovo Medical by leveraging our deep expertise in healthcare and life sciences, along with our global network, to help advance their mission of delivering novel cardiovascular solutions to patients in need worldwide." Cynthia Chen, Chairwoman and Executive Chair of Pulnovo Medical, stated: "We sincerely thank EQT and Qiming Venture Partners for their continued trust and partnership. Since day one, Pulnovo Medical has remained focused on addressing real, unmet clinical needs—developing original, scalable, and evidence-based solutions rooted in frontline care. While the path to transforming clinically driven innovation into global standards is challenging, we remain committed to delivering meaningful, science-based medical value to patients around the world."
Bloomberg
24-03-2025
- Business
- Bloomberg
Xiaomi-Backer Qiming Venture Seeks $800 Million in Funding
Qiming Venture Partners, the early backer of tech heavyweights Meituan and Xiaomi Corp., is seeking to raise about $800 million to ride a wave of renewed interest in Chinese AI startups, according to people familiar with the matter. The company will cap the fundraising at $1 billion, the people said, asking not to be named because the matter is private. The plans are preliminary and may change, they added. A representative for the fund declined to comment.
Yahoo
03-03-2025
- Business
- Yahoo
Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing
SHANGHAI, March 2, 2025 /CNW/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has announced the closing of nearly $100 million Series C financing. This round was co-led by Qiming Venture Partners and existing shareholder Lilly Asia Ventures, with existing investors OrbiMed and Gaorong Capital participating on a super pro-rata basis. The proceeds will be used to advance Pulnovo Medical's global clinical trials, international business expansion and strategic initiatives. The financing round was oversubscribed by two times, marking one of the largest fundraises in the Asia-Pacific innovative medical device sector in recent years. This reflects leading institutions' confidence in Pulnovo Medical's global strategy and technical capabilities. Founded in 2013, Pulnovo Medical is a pioneering medtech company recognized in international guidelines. The company leverages its extensive clinical expertise to drive scientific advancements and global commercialization. The company focuses on developing superior therapeutic solutions for various stages of HF to enhance patient outcomes. Pulnovo Medical's core product, PADN (Pulmonary Artery Denervation) technology, is an innovative and effective minimally invasive treatment for PH that has successfully obtained market is a condition that can lead to heart failure and mortality, with limited treatment options. PADN uses radiofrequency ablation to target the pulmonary vascular endothelial sympathetic nerve, effectively reducing pulmonary artery pressure and slowing disease progression. PADN received FDA Breakthrough Device designation for Group I, Group II, and Group IV PH in 2021. PADN was included in European Society of Cardiology and European Respiratory Society Guidelines in 2022. In 2023, Pulnovo Medical achieved the Humanitarian Use Exemption Device designation for Group I PH. The RF catheter and RF generator received market approval in China in late 2023, becoming a commercially available interventional device in the field globally. In 2024, Pulnovo Medical's accessory product, the 9F sheath, received FDA clearance. Cynthia Chen, Chairlady, Executive Chairwoman and President of Pulnovo Medical, announced that the proceeds of this round will support two upcoming FDA trials for Group I PH and Group II PH (chronic heart failure combined with PH) planned this year. Under the leadership of the executive team, the company has transformed from a laboratory to a globally structured firm with offices in the US, Singapore, as well as Hong Kong SAR and four cities in Chinese Mainland, including Beijing and Shanghai. William Hu, Managing Partner of Qiming Venture Partners, said, "Pulnovo Medical's breakthroughs in interventional treatments for PH and HF are impressive. The company's PADN technology is now commercially available in Chinese Mainland, Hong Kong, and Macau, and in 2024, global multicenter trials were initiated in Portugal, Serbia, Georgia, and Southeast Asia. Following the FDA Breakthrough Device designation, the global clinical trials further validate the technology's leadership and clinical value. As a long-term healthcare investor, Qiming is committed to supporting innovators with global visions. We are confident in Pulnovo Medical's potential and will support its international expansion and commercialization, bringing new hope to patients worldwide." View original content: SOURCE Pulnovo Medical View original content: Sign in to access your portfolio
